Cardiovascular Risk Reduction: With the 2023 approval for reducing major adverse cardiovascular events, GLP-1 receptor agonists are now used within comprehensive cardiovascular risk-management strategies for patients with type 2 diabetes and established cardiovascular disease
The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Small-molecule drugs can be incorporated into stimuli-responsive matrices or micelles to control release profiles while maintaining oral bioavailability [98]
Oshman also notes that the Bridge program doesnt require patients to be seen in person by the prescriber before receiving the prescription, nor that the prescriber have any relationship with the patient or experience prescribing under the Medicare system before prescribing the GLP-1 to them